345,340 Shares in Neogen Corporation $NEOG Acquired by Jackson Square Partners LLC

Jackson Square Partners LLC acquired a new stake in Neogen Corporation (NASDAQ:NEOG - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 345,340 shares of the company's stock, valued at approximately $1,651,000. Jackson Square Partners LLC owned about 0.16% of Neogen as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd lifted its position in Neogen by 388.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 10,071 shares of the company's stock valued at $87,000 after purchasing an additional 8,010 shares during the period. Savant Capital LLC bought a new stake in shares of Neogen during the second quarter worth approximately $50,000. Lindenwold Advisors INC acquired a new stake in Neogen during the 1st quarter worth $92,000. Angeles Wealth Management LLC acquired a new position in shares of Neogen in the 1st quarter valued at $99,000. Finally, Blue Trust Inc. lifted its stake in Neogen by 181.7% in the second quarter. Blue Trust Inc. now owns 11,974 shares of the company's stock valued at $57,000 after buying an additional 7,724 shares during the period. Institutional investors own 96.73% of the company's stock.

Analyst Upgrades and Downgrades

NEOG has been the topic of several recent analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Neogen in a research note on Wednesday, October 8th. Piper Sandler set a $6.50 price objective on Neogen and gave the stock a "neutral" rating in a research note on Thursday, October 16th. Zacks Research raised Neogen from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 20th. William Blair downgraded Neogen from an "outperform" rating to a "market perform" rating in a report on Tuesday, July 29th. Finally, Wall Street Zen upgraded Neogen from a "hold" rating to a "buy" rating in a report on Saturday, November 1st. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $8.83.

Get Our Latest Stock Analysis on Neogen

Neogen Stock Up 7.0%

NEOG stock opened at $6.40 on Friday. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -1.33 and a beta of 1.90. Neogen Corporation has a twelve month low of $3.87 and a twelve month high of $16.79. The business has a 50 day moving average price of $5.85 and a two-hundred day moving average price of $5.56. The company has a quick ratio of 2.26, a current ratio of 3.58 and a debt-to-equity ratio of 0.37.

Neogen (NASDAQ:NEOG - Get Free Report) last released its quarterly earnings data on Thursday, October 9th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.05 by $0.02. The company had revenue of $216.96 million during the quarter, compared to the consensus estimate of $203.93 million. Neogen had a positive return on equity of 2.23% and a negative net margin of 117.61%.The firm's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.07 EPS. Neogen has set its FY 2026 guidance at EPS. Analysts anticipate that Neogen Corporation will post 0.38 EPS for the current fiscal year.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Recommended Stories

• Five stocks we like better than Neogen
• REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today
• MarketBeat Week in Review – 11/03 - 11/07
• Business Services Stocks Investing
• OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever
• Why Are Stock Sectors Important to Successful Investing?
• 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail

Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Corporation (NASDAQ:NEOG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Neogen Right Now?

Before you consider Neogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.

While Neogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here